Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep;85(3):e62-e65.
doi: 10.1016/j.jinf.2022.06.012. Epub 2022 Jun 18.

Pediatric patients with immune-mediated diseases on immunosuppressants have low risk of severe COVID-19 and no increase in flare rate after SARS CoV-2 exposure

Alexis Virgil Cochino  1 , Oana Maria Farkas  2 , Andreea Ioan  3
Affiliations
Comment

Pediatric patients with immune-mediated diseases on immunosuppressants have low risk of severe COVID-19 and no increase in flare rate after SARS CoV-2 exposure

Alexis Virgil Cochino et al. J Infect. 2022 Sep.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram of the study: enrollment, inclusion and exclusion criteria, follow-up. Exposed: subjects with previously confirmed infection by RT-PCR or rapid antigen on the nasal-pharyngeal swab material AND subjects with positive anti spike antibodies at first or second evaluation during the first five months of the study. Unexposed: subjects with negative anti spike antibodies after one or two consecutive tests performed in the first five months.
Fig. 2
Fig. 2
The Kaplan Meier curves for flare-ups in the exposed and unexposed group. The 4-month risk of flare in the exposed and unexposed groups was 9% versus 14% (p = 0.45, Log Rank test). Flare-up evaluation started from the date of confirmed SARS CoV-2 infection (no more than six months) or from the first spike protein measure and lasted until study closure. Exposed: subjects with previously confirmed infection by RT-PCR or rapid antigen on the nasal-pharyngeal swab material AND subjects with positive anti spike antibodies at first or second evaluation during the first five months of the study. Unexposed: subjects with negative anti spike antibodies after one or two consecutive tests performed in the first five months. Flare-up: the need to modify previous treatment - initiate or increase dose of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids (systemic or local, as intra-articular glucocorticoid injection) or escalation of therapy from synthetic to biologic disease-modifying-anti-rheumatic-drugs (DMARDs).
See this image and copyright information in PMC

Comment on

References

    1. Zsigmond B, Breathnach AS, Mensah A, Ladhani SN. Very low rates of severe COVID-19 in children hospitalised with confirmed SARS-CoV-2 infection in London, England. J Infect. 2022 S0163-4453(22)00203-1. - PMC - PubMed
    1. Smith C, Odd D, Harwood R, et al. Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat Medicine. 2022;28:185–192. - PubMed
    1. Hospitalizations of children and adolescents with laboratory-confirmed COVID-19 COVID-NET, 14 States, July 2021–January 2022. Centers for disease control and prevention. Weekly report February 18, 2022. https://www.cdc.gov/mmwr/volumes/71/wr/mm7107e4.htm. - PMC - PubMed
    1. Estimated Flu-Related Illnesses, Medical visits, hospitalizations, and deaths in the United States — 2017–2018 Flu Season. Centers for disease control and prevention. Updated September 30, 2021. https://www.cdc.gov/flu/about/burden/2017-2018.htm.
    1. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19. Centers for disease control and prevention. Updated February 15, 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingco.... - PubMed

Substances